New progress in thrombolytic therapy of acute cerebral infarction details.doc

 PAGE \* MERGEFORMAT 11 New progress in thrombolytic therapy of acute cerebral infarction details [Keywords:] cerebral infarction thrombolytic therapy Tianjin Tasly Group, biotechnology and bio-products research and development center in Tianjin 300402 Cerebral infarction is a serious harm to human health of the major diseases is one of the first long-term disability cause of his death Death rate came in after myocardial infarction and cancer, ranking third in disease. The decisive factor is the formation of cerebral infarction Ischemic brain tissue the duration and severity. 75% of cerebral infarction was due to acute thrombosis or its It is the transfer of parts of the thrombus, leading to a result of regional cerebral vascular occlusion [1]. Cerebral infarction thrombolytic therapy is for early Artery occlusion period of reperfusion, recovery of blood supply, as far as possible to save the nerve function. With the neurology and thrombolytic agents in research and The development of thrombolytic therapy reduces infarct size and has become the most effective way to disability, especially for moderate and severe God The barrier effect is particularly significant for patients [2]. With the medical technology and biopharmaceutical technology development, has been developed The issuance of more advanced new thrombolytic drugs, such as foreign recombinant tissue-type plasminogen activator (rtPA), Recombinant pro-urokinase (rpro-UK) etc. the brain stem of thrombolytic therapy in a large-scale clinical trials, we have achieved good Good experimental results. In this paper, of thrombolytic therapy in cerebral infarction at home and abroad to do a brief overview of new progress. 1. The time window of thrombolytic therapy [3] Ischemic brain tissue pathological injury was progressive development, and therefore the timing thrombolysis time limit, that time window . Astrup is equal to 1981, made ischemic penumbra theory of the existence of time